1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 14 DECEMBER 2015

Cancer Drug News 14 DECEMBER 2015

  • December 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Leveraging Long-Term Data For Sustained Commercial Success
Industry Brief - Novartis To Begin Regulatory Submissions For Midostaurin In 2016
Industry Brief - Seattle Genetics To Move Novel ADC Into Phase III
Industry Brief - Genentech Reports Positive Pivotal Results From Venetoclax Phase II CLL Study
Industry Brief - Qinprezo Submitted To EMA For AML
Industry Brief - Milestone Triggered As FDA Approves Bendeka For CLL/NHL
Industry Trend Analysis - AbbVie Unlocking Imbruvica's Value
Industry Brief - Iclusig Phase III Trial Started In Second-Line Chronic Phase CML
Industry Brief - Amgen/Merck Enter Cancer Immunotherapy Collaboration
Industry Brief - Celgene/Astrazeneca Expand Immuno-Oncology Commitment
Industry Trend Analysis - Genomic Data Will Limit MM Market Size
Industry Brief - Lilly/Merck Expand Immuno-Oncology Collaboration
Industry Trend Analysis - Pfizer's Long-Term Oncology Position Not Limited By Xalkori
Industry Brief - Alecensa Launched In Japan
Industry Brief - HMP Initiates Fruquintinib Phase III Trial In NSCLC
Industry Brief - EMA Grants Orphan Drug Designation To Debio 1143
Industry Brief - Merck KGaA Initiates Two Phase III Studies Of Avelumab
Industry Brief - Merck KGaA Not to Pursue Evofosfamide Further In STS/PC
Industry Brief - XBiotech's Xilonix Meets Primary Endpoint In Phase III CRC Study
Industry Brief - Entrectinib Receives EU ODD For Neuroblastoma

Table Of Contents

Cancer Drug News 14 DECEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.